SEC Form 4 · accession 0001566049-19-000006
Arcturus Therapeutics Ltd. · ARCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph E Payne
Officer — President and CEO · 10% Owner
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566049
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $4.99 | Feb 7, 2019 | A | 60,000 | A | — | Feb 6, 2029 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The grant of options to the Reporting Person is subject to shareholder approval under the Companies Law 5759-1999 of the State of Israel; options vest over a period of four years from Vest Base Date, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter.